Prexasertib
- Generic Name
- Prexasertib
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N7O2
- CAS Number
- 1234015-52-1
- Unique Ingredient Identifier
- 820NH671E6
- Background
Prexasertib has been used in trials studying the treatment and basic science of mCRPC, Leukemia, Neoplasm, breast cancer, and Ovarian Cancer, among others.
Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
- Conditions
- Refractory Malignant Solid NeoplasmRecurrent Primary Central Nervous System NeoplasmChildhood Solid NeoplasmRecurrent Malignant Solid NeoplasmRefractory Primary Central Nervous System Neoplasm
- Interventions
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 30
- Registration Number
- NCT02808650
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6
- Registration Number
- NCT02778126
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Liverpool, United Kingdom
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 133
- Registration Number
- NCT02735980
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Florida Cancer Specialists and Research Institute, Saint Petersburg, Florida, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Conditions
- Chronic Myelomonocytic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent High Risk Myelodysplastic SyndromeRefractory High Risk Myelodysplastic SyndromeRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT02649764
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer
- Conditions
- Head and Neck Neoplasms
- Interventions
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT02555644
- Locations
- 🇺🇸
University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States
🇫🇷Gustave Roussy, Villejuif Cedex, France
🇫🇷Centre Leon Berard, Lyon, France
A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers
- First Posted Date
- 2015-08-03
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 12
- Registration Number
- NCT02514603
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 111
- Registration Number
- NCT02203513
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
- Conditions
- Breast CancerNeoplasm MetastasisColorectal Neoplasms
- Interventions
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 167
- Registration Number
- NCT02124148
- Locations
- 🇺🇸
Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
🇺🇸Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Phase 1 Study in Participants With Advanced Cancer
- Conditions
- Advanced CancerSquamous Cell CarcinomaCarcinoma, Squamous Cell of Head and NeckLung Squamous Cell Carcinoma Stage IVAnal Squamous Cell CarcinomaCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2016-05-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 150
- Registration Number
- NCT01115790
- Locations
- 🇺🇸
Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
🇺🇸Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.